Shanghai, China

Chunfeng Dai

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Theracosbio, LLC. Active years: 2026.

USPTO Granted Patents = 1 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Chunfeng Dai

Introduction

Chunfeng Dai is a notable inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceuticals, particularly in the formulation of medications. His innovative approach has the potential to enhance the effectiveness of existing drugs while minimizing side effects.

Latest Patents

Chunfeng Dai holds 1 patent related to pharmaceutical formulations. His patent focuses on the pharmacokinetic profile of the SGLT2 inhibitor bexagliflozin. By formulating it as an extended-release tablet, he has demonstrated that it can improve the drug's performance. Compared to standard immediate-release dosage forms, these tablets allow for a lower peak plasma concentration while maintaining therapeutic levels for a desired period. This advancement can enable the administration of lower doses while still achieving the same pharmacological effect.

Career Highlights

Chunfeng Dai is currently associated with Theracosbio, LLC, where he continues to work on innovative pharmaceutical solutions. His expertise in drug formulation has positioned him as a valuable asset in the industry. His work is characterized by a commitment to improving patient outcomes through scientific innovation.

Collaborations

Chunfeng collaborates with talented individuals such as Feng Wang and Ankit Shrivastava. Their combined efforts contribute to the advancement of pharmaceutical research and development.

Conclusion

Chunfeng Dai's contributions to pharmaceutical formulations exemplify the impact of innovation in medicine. His work not only enhances drug efficacy but also prioritizes patient safety and comfort.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…